Illumina News and Research

RSS

Teva signs agreement with Verinata Health for commercialization of verifi prenatal test in Israel

Illumina, Inc. today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi non-invasive prenatal test in Israel.

1 Jul 2013

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

14 Jun 2013

Illumina releases genomics cloud computing and storage platform

Illumina, Inc. today announced the full commercial availability of BaseSpace, the Company's genomics cloud computing and storage platform.

From Illumina, Inc. 16 May 2013

Rare mutation confers high risk of osteoporosis and certain cancers

deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University of Iceland reported today in the journal Nature the identification of a rare nonsense mutation that confers high risk of osteoporosis and osteoporosis related traits.

6 May 2013

Researchers use metagenomics to identify the cause of outbreaks of bacterial infection

Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli (STEC), which caused over 50 deaths in Germany, using an approach known as metagenomics which bypasses the need for growing bacteria in the lab.

12 Apr 2013

Illumina releases TruSight Tumor for NGS-based somatic variant detection in solid tumors

Illumina, Inc. today announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.

From Illumina, Inc. 4 Apr 2013

Genome sequencing reveals drug-resistant bacteria are transmitted from animals to humans

Researchers have used whole genome sequencing to reveal if drug-resistant bacteria are transmitted from animals to humans in two disease outbreaks that occurred on different farms in Denmark.

26 Mar 2013

Study on neoadjuvant cisplatin-based chemotherapy presented at 28th Annual EAU Congress

At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer.

18 Mar 2013

Researchers sequence entire gene to identify mutations that cause hyperinsulinism

Congenital hyperinsulinism is a genetic condition where a baby's pancreas secretes too much insulin. It affects approximately one in 50,000 live births and in severe cases requires the surgical removal of all or part of the pancreas.

28 Dec 2012

New England Biolabs launches new NEBNext Ultra kits at ASHG annual meeting

New England Biolabs, Inc. launched their new NEBNext "Ultra" kits at the recent American Society for Human Genetics annual meeting.

From New England Biolabs 17 Nov 2012

New federal funding enables researchers to unravel how humans develop cancers

A Simon Fraser University scientist working at one of Canada's first epigenomics mapping centres says new federal funding will accelerate researchers' ability to unravel how we develop some of the most common life threatening cancers.

26 Oct 2012

HDL may protect against abdominal aortic aneurysm

High levels of high-density lipoprotein cholesterol inhibit the formation of abdominal aortic aneurysm, findings from experimental mouse models suggest.

2 Oct 2012

Illumina launches new RNA sequencing kits

Illumina today introduced TruSeq Stranded mRNA and Total RNA Sample Preparation Kits for RNA sequencing. The new reagent kits enable researchers to quickly and easily conduct gene expression studies that provide a complete view of the transcriptome, even from low-quality RNA samples, such as formalin-fixed, paraffin-embedded (FFPE) samples.

From Illumina, Inc. 19 Sep 2012

Researchers hold new implications for pathogenesis of myotonic dystrophy

An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration between researchers at the IRCM, the Massachusetts Institute of Technology (MIT), the University of Southern California and Illumina.

13 Sep 2012

Eurofins MWG Operon acquires Illumina HiSeq 2500 and MiSeq sequencers

Eurofins MWG Operon, one of the pioneers and key providers of next generation sequencing (NGS), has added an Illumina HiSeq 2500 and an Illumina MiSeq sequencer to its fleet of NGS sequencers.

From Illumina, Inc. 5 Sep 2012

U.S. District Court rules in favor of Illumina over Helicos lawsuit

Illumina, Inc. announced today that District Judge Sue L. Robinson of the U.S. District Court for the District of Delaware granted Illumina's motion for summary judgment of invalidity of U.S. Patent No. 7,593,109, a patent asserted by Helicos BioSciences Corporation in a lawsuit filed against Illumina in October 2010. Judge Robinson ruled that the '109 patent was invalid for inadequate written description.

From Illumina, Inc. 30 Aug 2012

Novel genomic sequencing method can help conduct in-depth analysis of single cells

Only by viewing a Georges Seurat painting at close range can you appreciate the hidden complexities of pointillism - small, distinct dots of color applied to form an image from a distance. Similarly, biologists and geneticists have long sought to analyze profiles of genes at the single cell level but technology limitations have only allowed a view from afar.

23 Jul 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

Illumina launches new kits for targeted resequencing studies

Illumina, Inc. today introduced Nextera Exome and Custom Enrichment kits, the Company's latest targeted resequencing solutions offering sample preparation and enrichment in a single, integrated workflow.

From Illumina, Inc. 17 Jul 2012

Illumina launches RapidTrack WGS service

Illumina, Inc. today launched the RapidTrack Whole Genome Sequencing Service, a new offering in its FastTrack Sequencing Services operation that delivers a whole human genome in less than two weeks.

From Illumina, Inc. 21 Jun 2012